EssilorLuxottica SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000121667
EUR
282.10
-2.8 (-0.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About EssilorLuxottica SA stock-summary
stock-summary
EssilorLuxottica SA
Pharmaceuticals & Biotechnology
EssilorLuxottica SA, formerly known as Essilor International Compagnie Generale D Optique SA, is a France-based ophthalmic company. The Company designs, manufactures and markets a range of lenses, frames and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. The Company operates under a number of brands, including Ray-Ban, Oakley and Varilux, among others. The Company operates in Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.
Company Coordinates stock-summary
Company Details
147 rue de Paris , CHARENTON-LE-PONT None : 94220
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 9 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Leonardo Del Vecchio
Non-Executive Chairman of the Board
Mr. Francesco Milleri
Chief Executive Officer, Non-Independent Director
Mr. Paul du Saillant
Deputy Chief Executive Officer, Non-Independent Director
Mr. Hubert Sagnieres
Non-Executive Vice Chairman of the Board
Mr. Leonel Ascencao Pereira
Director - Representative of Employees
Mr. Romolo Bardin
Non-Independent Director
Ms. Juliette Favre
Director - Representative of Valoptec Association
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
708 Million
(Quarterly Results - Dec 2007)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 142,371 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

20.97%

stock-summary
Debt Equity

0.23

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

3.76